Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

033-23460	58732R 10 3
SEC FILE NUMBER	CUSIP NUMBER

þ Form 10-KSB

For Period Ended: October 31, 2006

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

MERA PHARMACEUTICALS INC
Full name of registrant

Former Name is Applicable

73-4460 QUEEN KA'AHUMANU HWY - SUITE 110 - KAILUA-KONA, HI 96740
Address of principal executive offices & zip code

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

(a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution reporton Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

PART III - NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q,10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The independent auditor’s review of the financial statements of Mera Pharmaceuticals, Inc. for the quarter ended October 31, 2006 will not be completed by the due date.

The Report on Form 10-KSB is expected to be filed on or before the fifth calendar day following the prescribed due date.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Gregory F Kowal	(808)	523-9422
(Name)	(Area Code)	(Telephone Number)

(2) Have all other periodic reports required under Section 1 3 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s).

þ Yes

o No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof ?

o Yes

þ No

Exhibits

None

MERA PHARMACEUTICALS INC
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.



Date: January 30, 2007	By:	/s/ Gregory F. Kowal
		Gregory F. Kowal Chief Executive Officer